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Aspergillus fumigatus is the most frequent fungus found in the sputum of cystic fibrosis (CF) subjects. Itraconazole is prescribed
for allergic bronchopulmonary aspergillosis (ABPA) or Aspergillus bronchitis in CF subjects. We hypothesized that A. fumigatus
isolates in the sputum of CF subjects with previous exposure to itraconazole was associated with higher prevalence of azole resis-
tance. From June 2010 to April 2011, sputum samples from adult CF subjects at Cochin University Hospital (France) were exam-
ined systematically for the detection of A. fumigatus. MICs of A. fumigatus isolates against azoles were screened using Etest, and
reduced susceptibility to azoles was confirmed using the CLSI broth microdilution method. A. fumigatuswas isolated from the
sputum of 131/249 (52.6%) adult CF subjects, and 47/131 (35.9%) subjects had received previous treatment with itraconazole.
Reduced A. fumigatus susceptibility to itraconazole (MIC,>2 mg/liter) was confirmed in 6/131 (4.6%) subjects. All 6 isolates
also had reduced susceptibility to posaconazole (MIC,>0.5 mg/liter), and 3/6 isolates had reduced susceptibility to voriconazole
(MIC,>2 mg/liter). Mutations in the cyp51A gene were detected at positions previously implicated to cause resistance in 5 iso-
lates. Azole-resistant A. fumigatus isolates were found in 5/25 (20%) subjects exposed to itraconazole within the previous 3
years. High rates of azole-resistant A. fumigatus isolates were present in adult CF subjects and were associated with recent itra-
conazole exposure. Although the clinical implications of these findings will require further studies, the cautious use of itracona-
zole in adult CF subjects can be recommended.
Aspergillus fumigatus is themost frequently found fungus in thesputum of cystic fibrosis (CF) subjects (18, 19). It has been
isolated from sputum samples from 56% of patients at our CF
center (19). A. fumigatus colonization has been associated with
allergic bronchopulmonary aspergillosis (ABPA) that occurred in
up to 15% of CF subjects (24). Furthermore, selected CF subjects
with Aspergillus colonization showed respiratory exacerbations,
which improved with antifungal therapy (22). Because the latter
subjects had noABPA, this conditionwas referred to asAspergillus
bronchitis (22). Although A. fumigatus colonization has not con-
sistently been associatedwith clinicalmanifestations in all CF sub-
jects (10), a recent report suggested that persistent A. fumigatus
infection was an independent risk factor for hospital admissions
(4). Thus, the interest on the impact ofA. fumigatus on respiratory
manifestations and use of antifungal therapy in CF subjects is
growing (13).
Azoles (including itraconazole, voriconazole, and posacona-
zole) are the only orally active therapies against A. fumigatus.
These antifungal agents have been proposed as an adjunctive
treatment to oral steroids in CF subjects with ABPA (12, 24), and
their use also was suggested for CF subjects with Aspergillus bron-
chitis (22). During the past 10 years, azole resistance has emerged
in A. fumigatus isolates (14) and has been associated with treat-
ment failure in subjects with aspergillosis (15). This increase in
azole-resistant A. fumigatus isolates was suggested to occur as a
consequence of increasing therapeutic or environmental exposure
to azoles (27). The frequency of azole-resistant A. fumigatus iso-
lates varied considerably among countries and diseases. For exam-
ple, studies in the United Kingdom (15) and the Netherlands (23)
have described high frequencies (5 to 6%) of azole resistance, es-
pecially in subjects with chronic aspergillosis (15). However, a
recent study in France identified a very low prevalence of resis-
tance to azoles in A. fumigatus collected from patients with inva-
sive aspergillosis who had been treated for hematological malig-
nancies (2).
Only limited data are available regarding the prevalence of
azole-resistant A. fumigatus isolates in CF subjects and their rela-
tionship to previous azole exposure. In a study performed in Por-
tugal, the authors tested 159 A. fumigatus isolates cultured from
the sputum of 11 CF patients (7 who never received antifungal
treatment and 4who received azoles) and foundno azole-resistant
isolates, leading the authors to conclude that antifungal resistance
appeared to be rare among CF patients (5). Another recent study,
which was performed in a large cohort of Danish CF subjects (n
133), reported that 4.5% of A. fumigatus isolates were azole resis-
tant (18). The authors underlined that all 6 of these patients pre-
viously had been exposed to azoles, and they concluded that the
emergence of azole resistance in the A. fumigatus isolates of CF
patients was of concern (18). Thus, there is conflicting evidence
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on the prevalence of azole-resistant A. fumigatus in CF subjects.
Furthermore, the impact of azole therapies on A. fumigatus resis-
tance to azole has not been established in CF subjects.
In the present study, we prospectively evaluated the azole sus-
ceptibility of A. fumigatus isolates in our cohort of adult CF sub-
jects. Our objectives were to evaluate the prevalence of A. fumiga-
tus isolates with reduced susceptibility to azoles and to examine
the impact of previous treatment with itraconazole on the azole
susceptibility of A. fumigatus isolates.
MATERIALS AND METHODS
Patients. From 1 June 2010 to 1 April 2011, all adult subjects attending
the CF center at Cochin Hospital (Paris, France) were recruited in this
prospective observational study. CF was diagnosed on the basis of
clinical manifestations with a sweat chloride concentration exceeding
60 mM and/or two disease-causing mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene (11). Clinical in-
formation was obtained using our CF center database. Clinical data
included age, gender, age at diagnosis of CF, CFTRmutations, pancre-
atic status, chronic airway colonization with Pseudomonas aeruginosa,
body mass index, and spirometry. Chronic A. fumigatus colonization
was defined as the presence of two or more positive sputum cultures
during the time of the study (4). Intermittent colonization was defined
as the presence of one positive sputum culture and at least one negative
culture during the time of the study. ABPA was defined according to
consensus criteria (24); subjects received itraconazole according to
international guidelines. In brief, Aspergillus colonization was treated
if it was symptomatic and no response was achieved with antibacterial
therapy (22). For subjects with ABPA, azole therapy was prescribed in
combination with systemic steroid therapy (24). Azole exposure was
considered present when a subject was treated for more than 2 weeks
with itraconazole, voriconazole, or posaconazole. We defined subjects
with recent exposure to itraconazole as subjects who received this
treatment (for at least 2 weeks) within the previous 3 years. Subjects
who received itraconazole before the previous 3 years were defined as
subjects with past itraconazole exposure. The study was approved by
the Institutional Review Board on Medical Research (CCTIRS 08-
370).
Culture and identification. Respiratory samples were cultured on
Sabouraud-chloramphenicol-gentamicin agar (bioMérieux, Marne la
Coquette, France) and incubated for 10 days at 27 and 37°C to recover
filamentous fungi, and cultures were inspected every day. A. fumigatus
was identified on the basis of macroscopic and microscopic morphology.
FIG 1 MICs of itraconazole, voriconazole, and posaconazole against A. fumigatus isolates obtained from the sputum of 131 CF subjects. Blue bars indicate
azole-susceptible isolates. Red bars indicate isolates in which resistance was confirmed by the CLSI broth dilution technique.
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Aspergillus fumigatus colonies showed blue-green-gray surface pigmenta-
tion, and microscopic examination showed septate hyphae with conidial
heads, which usually were columnar and uniseriate. Recently, novel
Aspergillus species with reduced azole susceptibilities and morphological
features resembling those of A. fumigatus have been described (3). To
confirm that Aspergillus isolates with reduced azole susceptibilities had
not been mistaken with other Aspergillus section Fumigati with primary
resistance to itraconazole (e.g., A. lentulus or A. viridinutans), we further
identified all isolates using matrix-assisted laser desorption ionization
time-of-flight (MALDI-TOF) mass spectrometry (1). This analysis con-
firmed that all isolates were A. fumigatus.
Susceptibility testing for azole resistance in A. fumigatus isolates.
Itraconazole, voriconazole, and posaconazole susceptibilities were deter-
mined initially using Etest strips according to the manufacturer’s instruc-
tions (AB Biodisk, bioMérieux, France) after 24 h of incubation at 37°C.
When more than one sputum samples had been tested for A. fumigatus
azole susceptibility in a single patient, we described the sample with the
highest itraconazole MIC. Isolates with itraconazole MICs of2 mg/liter
by Etest were further analyzed forMICs to itraconazole, voriconazole, and
posaconazole using the CLSI M38-A2 broth microdilution method (8).
We considered reduced susceptibilities to itraconazole and voriconazole
for MICs of 2 mg/liter and to posaconazole for MICs of 0.5 mg/liter
(20, 21, 26).
Mixed-format real-time PCR assay to detect A. fumigatus muta-
tions.All of theA. fumigatus isolates for which the CLSI itraconazoleMIC
was2mg/liter were subjected to amixed-format real-time PCR assay, as
described previously for the detection of mutations at positions in the
cyp51A gene known to cause triazole resistance in A. fumigatus (17).
Statistics. Continuous variables were reported as medians and inter-
quartile ranges (IQR) and were compared using the Wilcoxon rank-sum
orKruskal-Wallis test, as appropriate. Categorical variables were reported
as counts and percentages and were compared using Fisher’s exact tests.
Statistical analyses were two sided, and P  0.05 was considered to have
statistical significance. Analyses were performed using Stata 11.0 (Stata-
Corp LP, TX).
RESULTS
From 1 June 2010 to 1 April 2011, 570 sputum samples were pro-
spectively collected from 249 adult CF subjects. A. fumigatus was
present in 285/570 (50.0%) samples, corresponding to 131/249
(52.6%) individual CF subjects. During the study period, 97/131
(74%) subjects met criteria for chronic Aspergillus colonization
(2 A. fumigatus-positive sputum samples), and 19/131 (15%)
subjects had intermittent colonization. The remaining 15/131
(11%) had only one (positive) sample processed during the study
period.
Distribution of azole MICs, as determined by Etest, in subjects
with A. fumigatus isolates is provided in Fig. 1. A. fumigatus iso-
lates with Etest itraconazole MICs of 2 mg/liter were found in
16/131 (12.2%) subjects. These 16 isolates were further analyzed
using the CLSI reference broth microdilution, and reduced sus-
ceptibility to itraconazole was confirmed in 6/131 (4.6%) subjects.
A comparison of azole MICs between Etest and CLSI methods is
provided in Table 1. The 6 isolates with Etest MICs of4mg/liter
also had elevatedCLSIMICs to itraconazole, whereas isolates with
Etest MICs of 4 mg/liter had CLSI MICs to itraconazole of 2
mg/liter. A. fumigatus isolates with reduced susceptibilities to po-
saconazole (Etest MICs of 0.5 mg/liter) were found in 6/131
(4.6%) subjects, and all of these isolates were confirmed to be
resistant to posaconazole and itraconazole using the CLSI
method. Furthermore, 3 of these 6 isolates had reduced suscepti-
bility to voriconazole.
Characteristics of the 131 CF subjects positive for A. fumigatus
isolates are provided in Table 2. When comparing subjects har-
boring isolates with CLSI-confirmed reduced susceptibility to
itraconazole (n 6) to subjects with itraconazole-susceptible iso-
lates (n 125), no significant clinical or demographic difference
was found between groups. However, previous exposure to itra-
conazole was found in 42/125 (33.6%) subjects with CLSI itra-
conazole MICs of 2 mg/liter versus 5/6 (83.3%) subjects with
CLSI itraconazole MICs of 2 mg/liter (P  0.02). One isolate
from an itraconazole-nonexposed patient had the TR/L98H mu-
tation. The other 5 resistant isolates were from itraconazole-
exposed patients and involved G54E (n  1), M220I (n  1),
M220R (n 1), and TR/L98H (n 1); no known cyp51A muta-
tion was identified in 1 patient.
TABLE 1 Comparison of Etest and CLSI methods for determination of azole MICs in 16 isolates with Etest itraconazole MICs of2 mg/litera
Patient no.
MIC (mg/liter) and test method
cyp51Amutation
Itraconazole Voriconazole Posaconazole
Etest CLSI Etest CLSI Etest CLSI
1 32 16 1.5 16 2 8 Unknown
2 32 16 0.047 0.25 1.5 1 G54E
3 32 16 0.5 0.5 6 0.5 M220R
4 32 16 0.25 2 2 0.5 M220I
5 24 16 1.5 8 1 1 TR/L98H
6 12 16 1 8 1.5 1 TR/L98H
7 4 1 0.38 1 0.125 0.25
8 4 1 0.25 1 0.19 0.25
9 3 0.25 0.38 0.5 0.25 0.125
10 2 0.5 0.19 0.5 0.094 0.125
11 2 0.5 0.125 0.5 0.19 0.25
12 2 0.5 0.25 0.5 0.125 0.125
13 2 0.5 0.19 0.5 0.125 0.125
14 2 0.5 0.25 0.5 0.125 0.125
15 2 0.5 0.19 0.5 0.094 0.125
16 2 0.25 0.19 0.5 0.19 0.125
a Gray shading corresponds to isolates with reduced azole susceptibility. cyp51Amutations were assessed in the 6 isolates with CLSI-confirmed reduced susceptibility.
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We next examined the prevalence of azole-resistant A. fu-
migatus in CF subjects, taking into account previous exposure
to itraconazole. Forty-seven (35.9%) subjects had previously
received itraconazole therapy, 24 (51.0%) subjects for ABPA
and 23 (49.0%) subjects for Aspergillus bronchitis. The median
(IQR) duration of itraconazole therapy was 25.0 (11.0; 44.3)
months, and most subjects received 400 mg/day itraconazole.
Because we hypothesized that recent itraconazole therapy was
associated with the increased prevalence of azole-resistant iso-
lates, we compared subjects with recent (within the previous 3
years) itraconazole treatment to subjects with past itraconazole
treatment (but no treatment within the previous 3 years) and to
subjects who had never been treated with itraconazole (Table
3). Isolates with reduced susceptibilities to itraconazole (CLSI
MICs of2 mg/liter) were found in 1/84 (1.2%) and 0/22 (0%)
subjects without itraconazole treatment or with past itracona-
zole treatment, respectively. However, isolates with reduced
susceptibilities to itraconazole and to posaconazole were found
in 5/25 (20%) of subjects with recent itraconazole treatment
(P  0.003) (Table 3). No significant association was found
between the number of months on itraconazole or daily dosage
of itraconazole and reduced susceptibilities to itraconazole and
posaconazole (not shown).
DISCUSSION
In the present study, we prospectively examined azole susceptibil-
ities ofA. fumigatus isolates obtained from the sputumof adult CF
subjects. In this single-center cohort, we found that 4.6% of
subjects harboring A. fumigatus had isolates with reduced suscep-
tibilities to itraconazole. All of the isolates with reduced suscepti-
bilities to itraconazole also had reduced susceptibilities to po-
saconazole, and half of these isolates also were resistant to
voriconazole. A strong association was found between itracona-
zole treatment within the previous 3 years and reduced suscepti-
bilities to both itraconazole and posaconazole.
To the best of our knowledge, only three studies reported sys-
tematic screening forA. fumigatus azole susceptibilities in CF sub-
jects. Mortensen et al., who studied azole susceptibilities using an
itraconazole screening agar and the EUCASTmethod, found itra-
conazoleMICs of2mg/liter in 6/133 (4.5%) CF subjects withA.
TABLE 2 Characteristics of patients according to itraconazole MICs of A. fumigatus isolates
Variablea
Results for:
P values
All subjects
(n 131)
Subjects with
itraconazole-susceptible
isolates (n 125)
Subjects with
itraconazole-resistant
isolates (n 6)
Age (yr [IQR]) 27 [23; 35] 27 [23; 34] 23 [21; 36] 0.37
Age at CF diagnosis (yr [IQR]) 1.0 [0.2; 6.0] 1.5 [0.2; 6.0] 0.6 [0.2; 1.0] 0.53
CFTRmutation (no. [%])
F508del/F508del 56 (42.7) 53 (42.4) 3 (50.0) 0.89
F508del/other 56 (42.7) 54 (43.2) 2 (33.3)
Other/other 19 (14.6) 18 (14.4) 1 (16.7)
Male (no. [%]) 77 (58.8) 72 (57.6) 5 (83.3) 0.40
Pancreatic insufficiency (no. [%]) 112 (85.5) 107 (85.6) 5 (83.3) 1.00
FEV1 (% predicted [IQR]) 54 [39; 74] 55 [40; 73] 44 [21; 78] 0.36
FVC (% predicted [IQR]) 71 [55; 89] 72 [55; 89] 64 [34; 79] 0.28
Chronic P. aeruginosa (no. [%]) 75 (57.3) 70 (56.0) 5 (83.3) 1.00
Chronic A. fumigatus (no. [%]) 97 (74%) 93 (74.4) 4 (66.7) 0.65
ABPA (no. [%]) 28 (21.4) 25 (20.0) 3 (50.0) 0.11
Previous itraconazole therapyb (no. [%]) 47 (35.9) 42 (33.6) 5 (83.3) 0.02
Previous itraconazole therapyc (no. [%])
None 84 (64.1) 83 (66.4) 1 (16.7) 0.003
Past 22 (16.8) 22 (17.6) 0 (0)
Recent 25 (19.1) 20 (16.0) 5 (83.3)
Previous voriconazole therapyb (no. [%]) 7 (5.3) 5 (4.0) 2 (33.3) 0.20
Previous posaconazole therapyb (no. [%]) 0 0 0
Sputum samples/patient (median [IQR]) 3.0 [2.0; 4.0] 3.0 [2.0; 4.0] 3.5 [1.0; 5.0] 0.81
A. fumigatus-positive sputum samples/patient
(median [IQR])
2.0 [1.0; 3.0] 2.0 [1.0; 3.0] 3.5 [1.0; 5.0] 0.34
Itraconazole MIC
Median (IQR) by Etest 0.75 [0.50; 1.00] 0.75 [0.50; 1.00] 32.00 [24.00; 32.00] 0.001
MIC of2 mg/liter by CLSI (no. [%]) 6 (4.6) 0 (0) 6 (100)
Voriconazole MIC
Median (IQR) by Etest 0.125 [0.125; 0.190] 0.125 [0.125; 0.190] 0.750 [0.250; 1.500] 0.005
MIC of2 mg/liter by CLSI (no. [%]) 3 (2.3) 0 (0) 3 (50) 0.0001
Posaconazole MIC
Median (IQR) by Etest 0.094 [0.064; 0.125] 0.094 [0.064; 0.125] 1.75 [1.5; 2.0] 0.0001
MIC of0.5 mg/liter by CLSI (no. [%]) 6 (4.6) 0 (0) 6 (100) 0.0001
a FEV1, forced expiratory volume in 1 s. FVC, forced vital capacity.
b At any time point.
c Recent exposure, within the previous 3 years; past exposure, before the previous 3 years.
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fumigatus isolates (18). A recent Dutch study reported a preva-
lence of 4.2% azole resistance among 442 isolates after screening
with a real-time PCR (25). Amorim et al. studied 159A. fumigatus
isolates collected from the sputa of 11 adult CF patients using the
CLSI broth dilution method and reported no resistance to itra-
conazole or posaconazole (5). In the latter study, 4/11 patients had
isolates with itraconazole MICs of 2 mg/liter, indicating interme-
diate susceptibility to itraconazole, and A. fumigatus also had in-
termediate susceptibility to posaconazole in one of these patients
(5). Our findings confirmed that A. fumigatus isolates with re-
duced susceptibility to itraconazole were present among CF sub-
jects and extended previous data by showing that cross-resistance
to posaconazole and to voriconazole also was prevalent.
Subjects with reduced itraconazole susceptibility were more
likely to have received itraconazole therapy within the previous 3
years. This finding is in line with the report by Mortensen et al.,
who found that the 6 subjects with reduced A. fumigatus suscep-
tibility to itraconazole were previously exposed to itraconazole
(18). However, no data were provided on the rates of azole resis-
tance in subjects exposed to azole therapies (18). Here, we show
that reduced itraconazole and posaconazole susceptibilities were
present in 20% of subjects with recent itraconazole treatment.
These data suggest a major role for itraconazole therapy in the
selection of azole-resistant isolates.
Subjects with past treatment with itraconazole (but without
treatment within the previous 3 years) had no evidence of de-
creased azole susceptibility. In a recent study, de Valk et al. per-
formed the molecular typing of A. fumigatus isolates obtained
during longitudinal follow-up in 36 adult CF subjects (9). The
authors found that only 17% of the patients were chronically col-
onized with a single genotype, suggesting that in many subjects A.
fumigatus isolates were cleared but that recolonization with other
genotypes of A. fumigatus occurred (9). We speculate that the
clearance of A. fumigatus isolates, followed by the acquisition of
novel isolates, explains the low rates of reduced susceptibility to
itraconazole in CF subjects with past (but without recent) itra-
conazole treatment. It also is possible that azole resistance in A.
fumigatus isolates results in the alteration of growth and virulence
(loss of fitness), favoring their disappearance fromCF airways (6).
Further studies will be required to confirm these hypotheses.
The present study has several strengths. It was performed in a
prospective design in consecutive adult CF subjects with various
degrees of respiratory impairment. The size of the cohort allowed
the assessment of the impact of itraconazole exposure on azole-
resistant A. fumigatus. We also recognize limitations. Susceptibil-
ity to azoles was initially tested using Etest, which is not the refer-
ence method (8, 21). The confirmation of azole resistance was
obtained using the reference CLSI broth dilution technique. Al-
though isolates that had CLSI-confirmed azole resistance had the
highest Etest MICs (Table 1), our data suggest that breakpoints or
epidemiological cutoff values (ECVs) aremethod specific. The use
of Etest had the advantage of being commercially available, and it
can be routinely performed in most laboratories (14). However,
the confirmation of resistance using a broth dilution technique
and/or genetic analysis appears necessary until Etest-specific
breakpoints are established. Only 13/47 (27.6%) subjects with
itraconazole treatment had therapeutic drug monitoring, and
itraconazole concentrations were lower than recommended in 4
subjects (data not shown). Thus, we were unable to examine the
effect of long-term underdosing on azole susceptibility to A. fu-
migatus. Because azole plasma concentrationsmay be widely vari-
able in CF subjects receiving similar doses of azole therapies (7),
TABLE 3 Characteristics of patients according to itraconazole exposure
Variablea
Result according to itraconazole exposure
P values
No exposure
(n 84)
Past exposure
(n 22)
Recent exposure
(n 25)
Age (yr [IQR]) 27 [23; 36] 30 [27; 34] 24 [21; 37] 0.01
Age at CF diagnosis (yr [IQR]) 1.5 [0.2; 9.0] 1.4 [0.1; 7.0] 1.0 [0.2; 3.0] 0.39
Male (no. [%]) 50 (59.5) 14 (63.6) 13 (52.0) 0.73
Pancreatic insufficiency (no. [%]) 71 (84.5) 18 (81.8) 23 (92.0) 0.55
FEV1 (% predicted [IQR]) 58 [42; 74] 57 [34; 66] 48 [36; 78] 0.29
FVC (% predicted [IQR]) 75 [63; 92] 67 [54; 81] 62 [54; 83] 0.04
Chronic P. aeruginosa (no. [%]) 49 (58.3) 11 (50.0) 15 (60.0) 0.76
ABPA (no. [%]) 4 (4.8) 11 (50.0) 13 (52.0) 0.001
Voriconazole therapyb (no. [%]) 1 (1.2) 3 (13.6) 3 (12) 0.01
Posaconazole therapyb (no. [%]) 0 0 0
Sputum samples/patient (median [IQR]) 3.0 [2.0; 4.0] 3.0 [2.0; 4.0] 4.0 [3.0; 5.0] 0.008
A. fumigatus-positive sputum samples/patient
(median [IQR]
2.0 [1.0; 3.0] 2.5 [1.0; 4.0] 3.0 [2.0; 4.0] 0.24
Itraconazole MIC
Median (IQR) by Etest 0.750 [0.440; 1.000] 0.750 [0.500; 1.000] 1.000 [0.500; 2.000] 0.03
MIC of2 mg/liter by CLSI (no. [%]) 1 (1.2) 0 5 (20.0) 0.003
Voriconazole MIC
Median (IQR) by Etest 0.125 [0.125; 0.190] 0.158 [0.125; 0.190] 0.190 [0.125; 0.250] 0.50
MIC of2 mg/liter by CLSI (no. [%]) 1 (1.2) 0 2 (8.0) 0.17
Posaconazole MIC
Median (IQR) by Etest 0.094 [0.064; 0.125] 0.094 [0.064; 0.125] 0.125 [0.064; 0,19] 0.001
MIC of0.5 mg/liter by CLSI (no. [%]) 1 (1.2) 0 5 (20.0) 0.003
a FEV1, forced expiratory volume in 1 s. FVC, forced vital capacity.
b At any time point.
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the role of pharmacokinetic variability in the reduced azole sus-
ceptibility of A. fumigatus isolates will require further studies.
The molecular characterization of the azole-resistant isolates
identifiedmutations in the cyp51A gene (26), including TR/L98H,
and mutations at positions M220 and G54 (14). A variety of mu-
tations atM220 and G54 have been previously implicated as caus-
ing azole resistance (including G54R, G54E, G54W, G54V, G54K,
M220V, M220K, M220T, M220R, and M220I) and were associ-
ated with azole exposure. In contrast, the TR/L98Hmutation also
is described in azole-naïve patients and was present in one patient
without previous therapeutic exposure to itraconazole, suggesting
that it resulted from environmental exposure. One isolate, with
cross-resistance to itraconazole, voriconazole, and posaconazole,
had no mutation at any of the positions covered by the real-time
PCR-based screening assay (also including G138) (17). Further
studies will be necessary to determine the molecular basis of azole
resistance in this isolate.
Itraconazole therapy has been advocated in subjects with
Aspergillus bronchitis (22) and as an adjunctive treatment to oral
steroids in subjects with ABPA (24). These attitudes are based on
relatively short-term studies. However, many patients in our
study were treated for long periods, and the median time of itra-
conazole therapy was 25 months. Because exposure to itracona-
zole is associated with a marked increase in A. fumigatusMICs to
both itraconazole and posaconazole, we suggest that the benefits
of long-term treatment with itraconazole are uncertain. For ex-
ample, the in vitro resistance ofA. fumigatus to oral azole therapies
had been associated with treatment failure in subjects with asper-
gillosis (15). These findings may be particularly relevant for sub-
jects with severe CF in whom lung transplantation is associated
with a higher risk of invasive aspergillosis (16).
In conclusion, we found a prevalence of 4.6%azole-resistantA.
fumigatus isolates in CF adults, which was similar to studies in
Denmark and the Netherlands. Reduced susceptibilities to itra-
conazole and posaconazole were clearly associated with recent ex-
posure to itraconazole. We suggest that the in vitro testing of A.
fumigatus azole susceptibility should be performed systematically
when considering azole therapy in CF subjects. Although further
studies are clearly required, we speculate that a combination of
limiting azole therapy to short periods of time and themonitoring
of therapeutic drug concentrations will reduce the emergence of
azole-resistant Aspergillus isolates.
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